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Introduction
Small molecule modulators of  cystic fibrosis transmembrane regulator (CFTR) function for patients with spe-
cific genotypes are making a significant impact in the care of  patients with cystic fibrosis (CF) and are domi-
nating current CF drug development efforts. Appropriately designed phase 3 trials of  ivacaftor demonstrated 
that, in patients with gating mutations, this medication had profound effects on both CFTR function and 
clinical outcomes (1, 2). Prior to US Food and Drug Administration (FDA) approval of  this medication, the 
CF Foundation-Therapeutics Development Network (CF-TDN) designed the G551D Observational Study 
(GOAL) to test the real-world efficacy of  this medication, to collect biospecimens that could be used to identi-
fy biomarkers of  CFTR function and/or improved health, and to explore the use of  specific in vivo bioassays 
in substudies that may also reflect CFTR function and, thereby, prove useful for future drug development (3).
Mucociliary clearance (MCC), measured by γ scintigraphy after the inhalation of  radiolabeled parti-
cles, has been used extensively in CF to characterize the consequences of  CF lung disease and to assess 
the therapeutic potential of  inhaled drugs designed to improve the physiologic conditions, such as mucus 
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METHODS. We performed a multisite, prospective, observational study of ivacaftor, prescribed in 
patients with the G551D-CFTR mutation. Measurements of lung mucociliary clearance (MCC) were 
performed before and after treatment initiation (1 and 3 months), in parallel with clinical outcome 
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symptom scores.
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may help to predict improvements in lung function.
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hydration, which govern mucus clearance in vivo. In this study, we tested the hypothesis that CFTR activity 
plays a central role in controlling the clearance of  airway mucus by measuring MCC rates before and after 
ivacaftor treatment. We also examined the effects of  ivacaftor on the CF lung by characterizing treatment 
effects over time and, in particular, lung regions of  interest (ROI) that reflect large and small airway phys-
iologic responses. Finally, by comparing MCC results with other outcome measures, including clinical 
responses, we examined whether improvements in MCC are related to clinical improvements, which could 
potentially impact drug development pathways and provide a tool for personalization of  treatments. As 
a multicenter MCC study of  a potentially novel therapeutic for CF, this study should also provide insight 
into the feasibility of  using a multisite platform for evaluating new agents using MCC scans in the future.
Results
Baseline population description
Twenty-three participants consented to participate at the 4 sites. Twenty-two subjects completed baseline 
MCC assessments, and 21 completed all assessments. One subject experienced a severe pulmonary exacer-
bation before the baseline assessment and was excluded from further participation. One subject was exclud-
ed from further participation following the baseline MCC scan due to severe noncompliance with the study 
protocol (Figure 1). Table 1 provides baseline demographic data for the study population that completed at 
least 1 MCC assessment (n = 22).
Clinical response to ivacaftor
Clinical improvements following ivacaftor were observed in this study and were similar in magnitude to 
those observed in both randomized controlled studies and the overall GOAL study cohort in this popu-
lation (2–4). Specifically, significant improvements in lung function, nutritional parameters, and patient 
reported outcomes were noted, as shown in Table 2. The clinical response in our study population, there-
fore, appears to be representative of  the typical ivacaftor clinical response in G551D-CFTR patients.
Baseline MCC
Baseline rates of  MCC (AveClr60) were variable across the population but were not significantly different 
between study sites or subject sexes and did not correlate with baseline lung function (forced expiratory 
volume in the first second [FEV1] percent predicted). However, subjects who were chronically infected with 
Pseudomonas aeruginosa had significantly slower rates of  whole lung (WL) MCC, when compared with 
those who were either uninfected or intermittently infected (AveClr60 5.5 ± 4.9, n = 14; vs. 16.0 ± 9.4, n = 
5; P = 0.005). This finding is consistent with those reported in prior studies (5, 6).
Effect of ivacaftor on MCC
WL MCC. Figure 2 shows particle clearance over time in each lung region of  interest (ROI). MCC from the 
whole right lung through 60 minutes (AveClr60) (i.e., before voluntary coughs) was the primary outcome 
of  this study and was previously reported in the main study publication (3). Indeed, WL MCC as indexed 
by AveClr30, AveClr60, AveClr90, and 24-hour clearance markedly improved after initiating ivacaftor by 
the 1-month visit and remained at a similarly elevated rate at the 3-month visit (Table 3). Importantly, no 
significant differences in isotope deposition were detected when comparing baseline and posttreatment cen-
tral/peripheral (C/P) deposition ratio and skew of  the particle deposition histograms (Table 3). Further, 
there was no significant correlation between changes in deposition parameters (C/P ratio, skew) and the 
change in WL clearance. These data provide evidence that the observed acceleration in clearance did not 
result from a shift in isotope deposition toward the faster-clearing large airways. Examination of  individual 
subject MCC responses, and data trends from individual study sites, also supported the hypothesis that the 
impact of  ivacaftor was robust and not driven by subject outliers or site differences (Figure 3). Finally, the 
absence of  any differences between MCC parameters at 1 and 3 months after ivacaftor initiation supports a 
rapid (<1 month) and sustained effect that did not wane over time.
Regional assessments of  MCC. Examination of  regional MCC responses can provide an indicator of  the 
lung compartment (e.g., large vs. small airways) where a therapeutic agent has its greatest impact. The 
central lung ROI used in this study overlies the lung hilum and, therefore, includes the largest conducting 
airways. Therefore, analysis of  MCC from this ROI provided the opportunity to examine the effect of  iva-
caftor on MCC in a region that is enriched with large airways. Baseline rates of  MCC in this compartment 
were faster than in the WL compartment, given the intrinsically faster rate of  clearance from large airways. 
Following ivacaftor, central lung MCC rates were significantly increased at most time domains (i.e., Ave-
Clr30, AveClr60, AveClr90) when compared with baseline (Table 3).
MCC from the peripheral lung region excludes the largest airways located around the lung hilum and 
provides an assessment of  MC that reflects small airway function to a greater degree than WL clearance. 
We previously showed, using an identical MCC methodology, that MCC is predominantly affected in the 
peripheral lung in CF when indexed against a group of  healthy volunteers (7). In the current study, periph-
eral lung clearance was negligible at baseline, again consistent with the hypothesis that the small airways 
are the major site of  MCC dysfunction in CF. However, following ivacaftor, a profound (~7-fold) increase 
in peripheral lung MCC was observed (Table 3).
Cough clearance (CC). The ability of  cough to clear particles from the lower airways was assessed by 
having subjects forcefully cough 30 times during the 64- to 90-minute interval following isotope inhala-
tion. The total number of  coughs and peak flow rate during cough maneuvers did not change between 
baseline and postivacaftor (Vertex Pharmaceuticals) assessments. The percent clearance during this 
period was numerically increased after starting ivacaftor (Table 3) but not significantly different from 
baseline (P = 0.22). Of  note, this method of  assessing cough-driven clearance is limited by the fact 
that the extent of  particle clearance preceding the cough interval (i.e., from 0–64 minutes) has the 
potential to limit the availability of  cough-clearable particles (e.g., in central airways vs. distal airways 
or alveoli). Therefore, the faster rates observed after ivacaftor would create a bias against detecting an 
improvement in CC. On the other hand, cilia-driven clearance also contributes to the overall clear-
ance observed during the cough interval, and faster postivacaftor rates could account for the numer-
ical (nonsignificant) increases in clearance that were observed during the cough interval without any 
change in cough-mediated clearance whatsoever.
Predicting MCC responses by baseline characteristics
We explored whether the observed improvements in MCC in response to ivacaftor were predicted by base-
line subject characteristics. In fact, no relationships were observed when examining the potential effects of  
sex, age, baseline lung function, baseline sweat chloride, or chronic pseudomonas status. The change from 
baseline WL MCC (AveClr60) was significantly, though weakly, inversely correlated with baseline MCC 
(Spearman R = –0.37; P = 0.02). These data, therefore, suggest that MCC responses were similar across 
Figure 1. Study flow diagram.
patient groups and that patients with the most impaired MCC might be expected to experience the greatest 
improvements in MCC. Improvements in lung function (FEV1 percent predicted) were similarly unrelated 
to baseline lung function, age, sex, and chronic pseudomonas status.
Correlations between MCC responses and other endpoints
We next explored whether the observed changes in MCC in response to ivacaftor correlated with clinical 
outcomes, including lung function (FEV1). We employed a mixed model analysis to utilize data from all 
visits and to incorporate important covariates. In this model, incorporating change in WL AveClr60 and 
change in C/P (an important covariate that often influences MCC rates), a significant (P < 0.005) relation-
ship between the FEV1 and MCC changes was observed. Other potential covariates (e.g., age, sex, baseline 
FEV1) were not significant. The magnitude of  the effect of  AveClr60 on FEV1 suggested that the observed 
~10% absolute change in AveClr60 accounted for a 2.7% absolute increase in FEV1, or about one-quarter 
of  the total change in lung function. While accelerated MCC did not fully explain the observed improve-
ment in FEV1 in this model, it is perhaps not surprising given the intrinsic variability of  these in vivo end-
points, which would be expected to weaken the observed statistical relationship. Further, it is possible that 
different degrees of  MCC improvement could yield similar improvements in FEV1 (i.e., a threshold effect), 
which would also be expected to weaken the observed statistical relationship. Finally, ivacaftor could yield 
improvements in FEV1 through mechanisms that are completely independent from MCC. For example, 
direct smooth muscle and inflammatory cell effects have previously been postulated (8, 9)
Exploration of  other factors that could explain lung function improvements were also explored. The 
change in central lung, but not peripheral, MCC was similarly related to the change in FEV1. In contrast, 
as previously reported, changes in sweat chloride did not relate to the change in FEV1 (10, 11), nor were 
other significant relationships observed between changes in MCC parameters and changes in other clinical 
outcomes (e.g., Cystic Fibrosis Questionnaire – Revised [CFQ-R], Cystic Fibrosis Respiratory Symptom 
Diary [CFRSD], Sinonasal Outcome Tool [SNOT 20], BMI).
Discussion
Mutations in CFTR have been known to be the basis of  CF lung disease for nearly 3 decades. Two prominent 
hypotheses link CFTR to mucus transport via the regulation of  airway surface liquid (ASL) volume (12) and 
through bicarbonate secretion (13). Importantly, both of  these actions may play a role. Alternatively, CFTR 
has been linked to lung health via bacterial killing through the regulation of  ASL pH and the activity of  anti-
microbial substances (14). The approval of  ivacaftor as an effective modulator of  the G551D-CFTR mutation 
provided us the opportunity to directly test the hypothesis that CFTR function is tightly linked to MCC. 
Table 1. Demographics and baseline characteristics (n = 22)
Female n (%) 8 (34.8)
Age, years mean (SD) 25.2 (7.7)
Pediatric (age <18 years) subjects n (%) 4 (18.2)






Partially active CFTR mutation n (%) 2 (9.1)
BMI mean (SD) 21.9 (2.4)
FEV1 (l) mean (SD) 2.67 (1.20)
FEV1 (% predicted) mean (SD) 67.1 (24.6)
FVC (l) mean (SD) 3.88 (1.22)
FVC (% predicted) mean (SD) 92.9 (17.3)
Chronic HS use n (%) 12 (54.5)
Chronic dornase alfa use n (%) 15 (68.2)
FVC, forced vital capacity; HS, hypertonic saline.
Indeed, the large effect on MCC, which was fully realized at the 1-month time point and sustained thereafter, 
and similarly rapid improvements in clinical outcomes suggest that MCC is intimately linked to CFTR func-
tion. This study did not address the mechanism through which CFTR improves MCC, however.
The magnitude of  the MCC effect observed after ivacaftor was larger and more predictable (i.e., 
with fewer nonresponders) than when compared with inhaled therapies such as hypertonic saline (HS) 
(7, 15). Perhaps most notable was the marked increase in peripheral lung clearance observed after iva-
caftor (Figure 2C and Table 3). Importantly, peripheral lung clearance was negligible prior to ivacaftor 
treatment. After ivacaftor, however, robust peripheral lung clearance was observed. This is in agree-
ment with a recently published study that used a pixel-by-pixel analysis of  MCC to show that ivacaftor 
homogeneously increased clearance, regardless of  the baseline clearance rate in that pixel (16). We 
speculate, therefore, that the ability to effectively target distal lung regions via the systemic route pro-
vides an important efficacy advantage over inhaled therapies. In addition, ivacaftor’s marked impact 
on MCC and clinical outcomes may also reflect the fact that this drug directly targets CFTR, rather 
than alternative targets that incompletely substitute for missing CFTR functions. The normalization of  
peripheral lung clearance and large FEV1 improvement also suggests that, even in these patients with 
relatively advanced lung disease, a large reversible component exists. Thus, the continued development 
of  systemic therapies and improvements in the delivery of  inhaled therapeutics to small airways may 
be a key component to maximizing treatment responses.
Despite profound improvements in cilia-driven mucus clearance, we saw minimal improvement in CC. 
Although the nature of the MCC assay utilized in this study is not primarily designed to assess CC, and is there-
fore compromised by the preceding rate of cilia-driven mucus clearance, historical data suggests that a larger 
fraction of CC should be technically observable (17) but was not. We speculate that the lack of improvement 
in CC suggests that there are persistent abnormalities in mucus properties that are not corrected by improved 
CFTR function and the expected improvements in ASL hydration and/or pH. A deeper understanding of the 
physiologic properties that govern cough- versus cilia-driven clearance could shed light onto mucus properties or 
mucus-epithelial interactions that should be targeted by other therapeutics (e.g., mucolytics).
Our data demonstrate that measurements of  MCC are not only valuable tools for evaluation of  
CFTR modulator therapies, but that they can be reliably performed on a multisite basis. As the result 
of  careful procedure standardization, the technical quality of  images was high and interpretable data 
was uniformly obtained. Furthermore, between-site differences were not observed in this study, as was 
also the case in a previous study using these methods at 3 of  the involved sites (18). The availability 
of  a multisite MCC testing network may ultimately prove to be an efficient means of  demonstrating a 
relevant physiologic activity within the lung of  novel CFTR modulators or other therapeutics designed 
to improve MCC. Whether or not MCC scans will be sufficiently sensitive to detect MCC changes with 
less efficacious CFTR modulator regimens, or differentiate modulator regimens with only marginally 
different activities, is uncertain but is under investigation.
Table 2. Change in clinical endpoints
Baseline 1 month 3 months
FEV1 (l) 2.67 (1.20) 3.07 (1.28)
A 3.01 (1.28)A
FEV1 (% pred) 67.1 (24.6) 77.5 (25.6)
A 75.9 (25.1)A
Weight (kg) 63.6 (10.8) 65.3 (10.9)B 65.7 (10.8)B
BMI 21.9 (2.5) 22.5 (2.5)C 22.6 (2.2)A
Sweat chloride (mEq/l) 97.5 (16.5) 51.0 (17.6)A 47.5 (17.5)A
CFQ-R resp 66.9 (21.0) 77.5 (15.0)B 81.8 (14.4)A
CFRSD 31.6 (15.6) 24.2 (14.7)B 22.0 (13.6)A
SNOT-20 1.00 (0.67) 0.79 (0.76) 0.65 (0.66)B
Mix models were used to assess for changes in each parameter. When significant differences were observed, 
comparisons to baseline were performed and adjusted using Dunnett’s correction. AP < 0.001; BP < 0.01; CP < 0.05 versus 
baseline. CFQ-R Respiratory Domain, Cystic Fibrosis Questionnaire – Revised, respiratory symptom domain score. A 
higher score indicates improved respiratory symptoms. CFRSD, Cystic Fibrosis Respiratory Symptom Diary. A lower 
score indicates improved respiratory symptoms. SNOT-20, Sinonasal Outcome Test. A lower score indicates improved 
sinonasal symptoms.
Another important question is whether MCC scans can serve as a useful predictor of  clinical outcomes. 
Unlike sweat chloride measurements, or symptom scores, the change in WL and central lung MCC was 
significantly related to the observed change in FEV1, though it only explained ~25% of  the lung function 
effect. Although the heterogeneity of  CF lung disease is expected to reduce correlations between vari-
ous physiological endpoints, these data suggest for the first time to our knowledge that improvements in 
MCC may predict improvements in traditional measures of  lung function (i.e., FEV1). It is also possible 
that improvements in MCC may more closely relate to a therapy’s impact on pulmonary exacerbations, 
if  indeed these clinical events are related to encroachment of  disease into lung regions that previously 
functioned adequately (i.e., cleared mucus normally). This would be consistent with the apparent paradox 
observed with HS, where large sustained improvements in MCC and protection against exacerbations has 
been demonstrated but only small improvements in FEV1 have been observed (7, 19).
In summary, ivacaftor treatment provides substantial improvements in CFTR activity in patients with 
a gating-mutation that translate into profound improvements in MCC throughout all regions of  the CF 
lung. MCC changes were robust, not limited to patients with particular characteristics, and were sustained 
through 3 months of  treatment. Changes in whole and central lung clearance were significantly related to 
changes in FEV1, linking these physiologic endpoints for the first time to our knowledge. Finally, these data 
show that MCC measurements can be performed well within the context of  a multisite study and that these 
measurements may have value for the early phase assessment of  novel CF modulators.
Methods
A longitudinal, observational cohort study involving 28 centers within the CF-TDN was performed to capture 
clinical measures and biospecimens (core study) in CF patients age 6 and older with at least 1 copy of the 
G551D mutation and no prior exposure to ivacaftor (3). The impact of ivacaftor on MCC and the relationship 
between MCC changes and clinical outcomes was investigated in this nested substudy at 4 centers (UNC, Johns 
Hopkins University, University of Pittsburgh, and University of Alabama at Birmingham). WL MCC results 
after 1 month of treatment was previously published with the larger core study findings (3).
Figure 2. Mean clearance versus time curves. Mean clearance versus time curves (± SEM) in (A) whole lung, (B) central 
lung, and (C) peripheral lung regions of interest.
Core study. Clinical assessments included spirometry, body weight, sweat chloride analysis, and 3 
patient-reported outcome instruments: Cystic Fibrosis Questionnaire-Revised (CFQ-R) (20), Cystic Fibro-
sis Respiratory Symptom Diary (CFRSD) (21), and Sino-Nasal Outcome Test-20 (SNOT-20) (22). These 
assessments were conducted at up to 2 baseline visits and then at 1, 3, and 6 months after initiation of  
ivacaftor. Spirometry was performed according to American Thoracic Society standards (23), and percent 
predicted values were calculated using reference equations (24, 25).
MCC study design. Mucociliary and CC was measured using γ scintigraphy at baseline and following 1 and 
3 months of  ivacaftor therapy at 4 study sites. All sites received on-site training, followed a standard operating 
procedure (18), and used identical equipment for the delivery of  the radioisotope. Subjects were required to 
withhold use of  HS and dornase alfa (Genentech) at least 12 hours before each MCC study and resumed their 
use only after collection of  the final MCC data point (24 hours after inhalation of  the radioisotope). Subjects 
were also required to be clinically stable without new symptoms or pulmonary interventions for 14 days. The 
change in the average rate of  MCC between 0–60 minutes after isotope inhalation (AveClr60) between base-
line and 1 month after beginning ivacaftor treatment was the predefined primary outcome.
MCC assessment via γ scintigraphy. A standard operating procedure was developed for this study, using 
methods described previously (18, 26). Briefly, a planar Co57 source was used to obtain a transmission 
scan to delineate the lung contour and establish defined ROI (i.e., peripheral and central lung regions). 
Technetium-99m–labeled (Tc99m-labeled) sulfur colloid particles were delivered to the subject via DeVilbiss 
646 nebulizer, Pulmoaid compressor, and SPIRA dosimeter (0.7-second pulse during inspiration after 100 
ml delay). An electronic flow meter with a visual display and a metronome were used to target a defined 
inspiratory flow rate (rate [ml/s] = 3 × height in cm; rounded to nearest 100 ml/s) and breathing pattern (1 
second inspiration; 1 second expiration). Serial 2-minute images were then obtained for 64 minutes while 
encouraging the subject to refrain from coughing. The subject was then asked to forcefully cough through a 
peak flow device 10 times, every 10 minutes, while continuing to acquire γ images for an additional 30 min-
utes (30 total coughs) to assess CC. The subject returned 24 hours (± 6 hours) after inhaling the radioiso-
tope to assess particle retention at this time point. To avoid the confounding effects of  stomach activity on 
the left lung, particle clearance from the right lung was calculated following correction for isotopic decay. 
All image analyses were performed at a central site (UNC).
Defining lung ROI and characterizing regional isotope deposition. The 2-dimensional images obtained via γ 
scintigraphy were parsed into WL, C, and P ROI. In this way, the initial pattern of  isotope deposition, a 
factor that could potentially confound the analysis of  particle clearance, was assessed. Clearance from the 
C and P regions also was calculated to assess ivacaftor effects in lung regions relatively enriched with large 
and small airways, respectively.
Table 3. Mucociliary clearance parameters
MC parameter Baseline (n = 22) 1 month (n = 21) 3 month (n = 21)
Whole lung AveClr30 % 5.9 (7.5) 14.9 (9.5)A 13.2 (7.4)B
Whole lung AveClr60 % 8.5 (8.0) 18.7 (10.9)A 17.7 (8.1)A
Whole lung AveClr90 % 10.5 (8.2) 21.6 (11.7)A 21.0 (9.0)A
Whole lung 24-hr Clr % 28.7 (19.3) 36.1 (20.6) 46.5 (18.1)B
Central ROI AveClr30 % 13.6 (11.9) 21.4 (14.4)C 21.9 (10.2)C
Central ROI AveClr60 % 16.4 (12.6) 26.2 (14.9)B 27.2 (9.9)B
Central ROI AveClr90 % 19.3 (13.2) 29.7 (14.7)B 31.3 (9.7)B
Peripheral ROI AveClr30 % –0.8 (9.0) 9.2 (7.6)B 5.4 (11.4)
Peripheral ROI AveClr60 % 1.5 (8.7) 12.2 (9.3)B 9.1 (11.4)C
Peripheral ROI AveClr90 % 2.8 (8.5) 14.6 (10.4)A 11.7 (12.0)B
Cough clearance % 3.5 (5.7) 6.9 (9.3) 6.7 (10.2)
C/Pnorm ratio 2.00 (0.74) 2.13 (0.88) 2.18 (0.62)
Deposition skew 1.49 (0.62) 1.61 (0.76) 1.77 (0.79)
Mix models were used to assess for changes in each parameter. When significant differences were observed, 
comparisons to baseline were performed and adjusted using Dunnett’s correction. AP < 0.001; BP < 0.01; CP < 0.05  
versus baseline.
The Co57 transmission scan was used to identify and outline the WL field and to create C and P ROI. 
A rectangular region encompassing the entire right lung was created to define the WL region. A smaller 
rectangle that included 25% of  the WL area was aligned and centered on the interior boundary of  the WL 
region to define the C ROI (27). The remainder of  the lung field was defined the as the P ROI.
Isotope deposition was characterized using a normalized C/P ratio (C/Pnorm). To do this, the C/P ratio, 
obtained by dividing the number of  Tc99m counts on the initial γ image following isotope inhalation in the C 
and P regions (i.e., [C/P]Tc), was normalized to tissue attenuation in each ROI using the C/P ratio of  Co
57 
counts on the preceding transmission scan )i.e., [C/P]trans):
(C/P)Tc/(C/P)trans = C/Pnorm.
The relative intensity of  signal on a transmission image has been shown to be a useful surrogate for that 
region’s lung volume (as reported by Xenon equilibrium scans) when normalizing C/P ratios (27). The result-
ing normalized C/P ratio provides an index of  relative deposition in the central and peripheral lung regions 
that may then be used to assess deposition patterns at different study visits. Particle deposition is also used as 
a covariate in MCC analyses because MCC tends to be faster in central airways than in peripheral airways. 
As an independent assessment of  deposition pattern heterogeneity, a histogram of radioactive counts in each 
pixel of  the initial deposition in the whole right lung image following Tc99m inhalation was constructed, and 
the skew of its distribution was calculated (28).
Analysis of  regional MCC and CC. The retention (Rt)of  radioactive counts in each ROI (WL, C, P) at 
sequential time points was corrected for isotopic decay and background radiation and was then expressed 
as a fraction of  the initial counts. Percent clearance values were calculated from these retention values: 
100 × (1 – Rt). Percent clearance at designated 10-minute intervals throughout the 94-minute period was 
determined using the sum of  two 2-minute images that followed each 10-minute interval (Figure 2). Twen-
ty-four–hour clearance values were obtained using a 30-minute image at this time point. To describe each 
clearance vs. time data set, the average percent clearance over the first 30-, 60-, and 90-minute periods 
of  observation were computed using each 10-minute data point. These computed values — identified as 
AveClr30, AveClr60, and AveClr90, respectively — are proportional to the AUC and represent the average 
clearance at the midpoint of  each period of  clearance vs. time observation (18).
Radioisotope clearance between 64 and 94 minutes of  the MCC scan reflects the combined effects of  
cilia and CC. Because the preceding period of  isotope clearance (0–64 minutes) determines the amount of  
tracer available to be cleared during this CC period, the Rt value between 60 and 90 minutes was normal-
ized for each scan to the same starting point:
CC = 100 × ([1 – (Rt/Rt60min]).
The total number (voluntary + spontaneous) and force of  coughs (peak flow of  every fifth effort) were 
recorded to allow assessment of  these potential confounders.
Statistics. Mixed models were used to compare MCC parameters, deposition indices, and clinical 
outcomes measured at baseline and after ivacaftor (1 and 3 months) using “visit” as the fixed effect and 
“subject” as the random effect. Comparisons to baseline were performed and adjusted using Dunnett’s 
correction. P values below 0.05 were considered significant. Similarly, mixed models (exploratory variable 
and visit as fixed effects; subject as random effect) were used to assess the effect of  clinical parameters 
(e.g., baseline FEV1, sex, chronic pseudomonas infection status) on baseline MCC parameters and MCC 
Figure 3. Waterfall plot of the absolute change. Waterfall plot of the absolute change in whole lung AveClr60 from 
baseline at 1 (A) and 3 (B) months, color coded by study site. Distributions demonstrate robust effect of ivacaftor on 
MCC that is not driven by site differences.
responses to ivacaftor. Finally, mixed models were also used to examine the relationship between measured 
changes in MCC and clinical outcomes (e.g., lung function). The significance of  relationships between 
individual variables was tested using nonparametric Spearman’s rank correlation analysis. All values are 
expressed as the mean ± SD unless noted otherwise. Statistical calculations were performed using JMP Pro 
v13.0 (SAS Institute Inc.).
Study approval. All participants (and their guardians, as applicable) provided written informed consent, 
and the study was approved by IRBs at University of  North Carolina at Chapel Hill, Johns Hopkins School 
of  Medicine, University of  Pittsburgh School of  Medicine, and University of  Alabama at Birmingham 
School of  Medicine (ClinicialTrials.gov, NCT01521338).
Author contributions
SHD, SMR, and WDB led the study design. SHD, BLL, TEC, PB, KZ, AC, PLZ, PJM, MB, LWL, MMM, 
JMP, BF, SMR, and WDB contributed to data collection, and data interpretation for this manuscript. SHD, 
KZ, AC, and WDB performed analyses. SHD and WBD drafted the manuscript. BLL, TEC, KZ, AC, 
PLZ, and SMR also wrote and edited the manuscript.
Acknowledgments
This work was supported by the CFF Therapeutics, with support from P30 DK065988 at UNC; P30 
DK072482 and UL1TR001417 at UAB; UL1TR001079 at Johns Hopkins University; and P30 DK072506 
and UL 1RR024153 at University of  Pittsburgh. The investigators would like to acknowledge the Thera-
peutics Development Network Coordinating Center (Seattle, Washington, USA), for their invaluable assis-
tance and Sonya Heltshe for helpful discussions. Finally, the authors wish to acknowledge the contributions 
of  patients and families who participated in this study, as well as research coordinators and technicians 
who contributed to this work.
Address correspondence to: Scott H. Donaldson, 300 Meadowmont Village Circe, Suite 204, Chapel Hill, 
North Carolina 27517, USA. Phone: 984.974.9198; Email: Scott_Donaldson@med.unc.edu.
PLZ’s present address is: Department of  Pediatrics, National Jewish Health, Denver, Colorado, USA.
LWL’s present address is: Department of  Medicine, Ohio State University, Columbus, Ohio, USA.
1. De Boeck K, et al. Efficacy and safety of  ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst 
Fibros. 2014;13(6):674–680.
2. Ramsey BW, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 
2011;365(18):1663–1672.
3. Rowe SM, et al. Clinical mechanism of  the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in 
G551D-mediated cystic fibrosis. Am J Respir Crit Care Med. 2014;190(2):175–184.
4. Davies JC, et al. Efficacy and safety of  ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J 
Respir Crit Care Med. 2013;187(11):1219–1225.
5. Laube BL, Sharpless G, Benson J, Carson KA, Mogayzel PJ. Mucus removal is impaired in children with cystic fibrosis who 
have been infected by Pseudomonas aeruginosa. J Pediatr. 2014;164(4):839–845.
6. Locke LW, et al. Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung. Eur Respir J. 
2016;47(5):1392–1401.
7. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic 
fibrosis with hypertonic saline. N Engl J Med. 2006;354(3):241–250.
8. Cook DP, et al. Cystic Fibrosis Transmembrane Conductance Regulator in Sarcoplasmic Reticulum of  Airway Smooth Muscle. 
Implications for Airway Contractility. Am J Respir Crit Care Med. 2016;193(4):417–426.
9. Pohl K, et al. A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR 
potentiator therapy. Blood. 2014;124(7):999–1009.
10. Durmowicz AG, Witzmann KA, Rosebraugh CJ, Chowdhury BA. Change in sweat chloride as a clinical end point in cystic 
fibrosis clinical trials: the ivacaftor experience. Chest. 2013;143(1):14–18.
11. Barry PJ, Jones AM, Webb AK, Horsley AR. Sweat chloride is not a useful marker of  clinical response to Ivacaftor. Thorax. 
2014;69(6):586–587.
12. Boucher RC. Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med. 2007;261(1):5–16.
13. Quinton PM. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet. 2008;372(9636):415–417.
14. Pezzulo AA, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature. 
2012;487(7405):109–113.
15. Trimble AT, et al. Hypertonic saline has a prolonged effect on mucociliary clearance in adults with cystic fibrosis. J Cyst Fibros. 
2018;17(5):650–656.
16. Bennett WD, et al. Homogeneity of  Aerosol Deposition and Mucociliary Clearance are Improved Following Ivacaftor Treat-
ment in Cystic Fibrosis. J Aerosol Med Pulm Drug Deliv. 2018;31(4):204–211.
17. Bennett W, Zeman K, Donaldson SH, Donohue JF, Knowles MR, Boucher RC. Cough Clearance is Less Effective in Cystic 
Fibrosis than Chronic Bronchitis. Am J Resp Crit Care Med. 2004;169(7):A386.
18. Bennett WD, et al. Multisite comparison of  mucociliary and cough clearance measures using standardized methods. J Aerosol 
Med Pulm Drug Deliv. 2013;26(3):157–164.
19. Elkins MR, et al. A controlled trial of  long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 
2006;354(3):229–240.
20. Quittner AL, Buu A, Messer MA, Modi AC, Watrous M. Development and validation of  The Cystic Fibrosis Questionnaire in 
the United States: a health-related quality-of-life measure for cystic fibrosis. Chest. 2005;128(4):2347–2354.
21. Goss CH, Edwards TC, Ramsey BW, Aitken ML, Patrick DL. Patient-reported respiratory symptoms in cystic fibrosis. J Cyst 
Fibros. 2009;8(4):245–252.
22. Piccirillo JF, Merritt MG, Richards ML. Psychometric and clinimetric validity of  the 20-Item Sino-Nasal Outcome Test (SNOT-
20). Otolaryngol Head Neck Surg. 2002;126(1):41–47.
23. [No authors listed]. Standardization of  Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med. 
1995;152(3):1107–1136.
24. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of  the general U.S. population. Am J 
Respir Crit Care Med. 1999;159(1):179–187.
25. Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG. Pulmonary function between 6 and 18 years of  age. Pediatr Pulmonol. 
1993;15(2):75–88.
26. Donaldson SH, Corcoran TE, Laube BL, Bennett WD. Mucociliary clearance as an outcome measure for cystic fibrosis clinical 
research. Proc Am Thorac Soc. 2007;4(4):399–405.
27. Zeman KL, Wu J, Donaldson SH, Bennett WD. Comparison of  133 xenon ventilation equilibrium scan (XV) and 99m techne-
tium transmission (TT) scan for use in regional lung analysis by 2D gamma scintigraphy in healthy and cystic fibrosis lungs. J 
Aerosol Med Pulm Drug Deliv. 2013;26(2):94–100.
28. Bennett WD, Xie M, Zeman K, Hurd H, Donaldson S. Heterogeneity of  Particle Deposition by Pixel Analysis of  2D Gamma 
Scintigraphy Images. J Aerosol Med Pulm Drug Deliv. 2015;28(3):211–218.
